Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II TORTUGA trial of filgotinib in ankylosing spondylitis meets primary efficacy endpoint

Sep. 6, 2018

Phase III study of PET imaging agent flortaucipir F 18 meets primary endpoints

Sep. 6, 2018

Phoenix PharmaLabs receives support to study PPL-103 for cocaine addiction

Sep. 6, 2018

DSMB recommends continuation of phase IIb study of OPT-302 in wet AMD

Sep. 6, 2018

AIC-649 stimulates the immune system of patients with chronic HBV in phase I trial

Sep. 6, 2018

Adocia reports phase I data on BioChaperone Pramlintide Insulin in type 1 diabetes

Sep. 6, 2018

OncoArendi Therapeutics presents new AMCase and CHIT1 dual inhibitors for lung diseases

Sep. 6, 2018

Enanta Pharmaceuticals divulges new NR1H4 agonists

Sep. 6, 2018

Argenx initiates phase III trial of efgartigimod in generalized myasthenia gravis

Sep. 6, 2018

Daewoong Pharmaceutical patents EPRS inhibitors

Sep. 6, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....